Rob Davis, Merck CEO (The Galien Foundation)
February 1, 2024 11:13 AM EST
Deals
Pharma

Mer­ck still on the hunt for bil­lion-dol­lar deals, cit­ing Prometheus and Dai­ichi Sankyo as ex­am­ples

Katherine Lewin

News Reporter

Mer­ck is still in pur­suit of deals of a sim­i­lar size and scope to the com­pa­ny’s ac­qui­si­tions of Prometheus Bio­sciences and Ac­celeron, and is will­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times